JP Morgan Maintains Overweight on Cellebrite DI, Raises Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Brian Essex maintains an Overweight rating on Cellebrite DI (NASDAQ:CLBT) and raises the price target from $15 to $17.
August 16, 2024 | 3:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan analyst Brian Essex maintains an Overweight rating on Cellebrite DI and raises the price target from $15 to $17.
The Overweight rating and increased price target from a reputable analyst at JP Morgan is likely to boost investor confidence and positively impact the stock price of Cellebrite DI in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100